Certainly, there's no chance Omrix' Evithrom can be so packaged.
I now wonder if xrymd's view that the need for Evithrom to be thawed is a "deal breaker" is shared by the majority of surgeons? If so, I'd think Evithrom is DOA. And that would be a huge market research gaffe by Omrix and J&J. Are they really that stupid, or are we missing something?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.